MET and neoplasm: Although mock-infected organoids show a drop in viability when treated with the combination of erlotinib and PLX, negatively correlating with increasing concentration of PLX, tumor organoids expressing cMET were resistant to this combined treatment regimen (Fig 4F), but regained sensitivity when MET-inhibitor crizotinib was added20 (Appendix Fig A2).